

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
$43.15
Price+4.05%
$1.68
$4.401b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-33.3%
3y CAGR-5.9%
5y CAGR-$353.428m
-43.5%
1y CAGR-38.4%
3y CAGR-29.3%
5y CAGR-$3.22
-30.4%
1y CAGR-14.8%
3y CAGR-1.5%
5y CAGR$244.995m
$411.718m
Assets$166.723m
Liabilities$110.076m
Debt26.7%
-0.3x
Debt to EBITDA-$274.644m
-36.6%
1y CAGR-27.9%
3y CAGR-21.2%
5y CAGR